Loading…
← CockpitCompetitor Analysis › 2616.HK CStone PharmaceuticalsOpen in the cockpit ↗

CStone Pharmaceuticals2616.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Chinese oncology biotech behind sugemalimab (PD-L1 inhibitor), commercialized in China with Pfizer.

≈ A Chinese oncology biotech partnered with a US pharma major for distributionMomentum leader 84
Mkt cap
$1.21B
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$4.63M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 9.4%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · HKDHK$5.89
1D+8.0%
1W+7.6%
1M+15.9%
3M+15.1%
6M-22.1%
YTD+11.9%
1Y+6.8%
ATR %6.2%
52w lowhigh43.4% off high

What CStone Pharmaceuticals does

Chinese oncology biotech behind sugemalimab (PD-L1 inhibitor), commercialized in China with Pfizer.

In one line: A Chinese oncology biotech partnered with a US pharma major for distribution.

Products and services

  • Sugemalimab (PD-L1 inhibitor)
  • Oncology pipeline

Customers

  • Hospitals/oncologists in China
  • Pfizer (China commercialization partner)

Where it sits in the supply chain

  • Biotechnology
  • Immuno-oncology antibodies
  • Branded biologics

What could go right

  • Sugemalimab sales ramp via Pfizer distribution

What could go wrong

  • Competitive PD-1/PD-L1 pricing
  • Clinical trial risk

Moat: narrow (IP / patents, regulatory licence). Approved PD-L1 antibody with patent protection and a major-pharma distribution partner.

Headquarters: Suzhou, China · Founded: 2015 · Employees: 93

Named competitors

CStone Pharmaceuticals at a glance

Size CStone Pharmaceuticals (2616.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.21B, the 531st largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$5.89 on 18 Nov 2026.

Performance Over six months the shares fell 22.1%, against -17.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue grew 116.7% over the last twelve months (peer median +5.9%); the operating margin is -88.7% (peer median 0.8%).

Valuation It trades at 17.0× enterprise value to sales against a peer median of 7.6× (3rd most expensive of 18).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 852616.HK 76
Six months, rebased to 100: CStone Pharmaceuticals against the median of its 20 peers (local-currency closes).

CStone Pharmaceuticals financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$475MHK$292MHK$442MHK$513MHK$560M
Revenue growth—-34%-14%-8%—
Gross profitHK$218MHK$7.88MHK$206MHK$315MHK$299M
EBITDA-HK$372M-HK$403M-HK$49.4M-HK$605M-HK$997M
Net income-HK$470M-HK$474M-HK$98.9M-HK$406M-HK$1.05B
Free cash flow-HK$315M-HK$356M-HK$335M-HK$711M-HK$833M
Capital expenditureHK$0HK$0HK$0HK$71.9MHK$118M
Total debtn/aHK$403MHK$386MHK$400MHK$321M

Quarterly statements and history in the cockpit →

CStone Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%300006HROW2493347850IDIA300026688321688443AVLNNKTR6855GPCR000950000989GHRSAMPH45470023322616.HK6-month return →1-month return →
Up and to the right = strong over both horizons. CStone Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%0×250×500×750×300006HROW34785030002668844368553002042616.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CStone Pharmaceuticals is the large dot.

CStone Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (2616.HK vs 1877.HK vs 1801.HK vs 9926.HK)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
CStone Pharmaceuticals 2616.HK$1.21B-22%+117%-89%17.0×n/a
Shanghai Junshi Biosciences 1877.HK$3.49B-38%+36%-14%8.4×n/a
Innovent Biologics 1801.HK$18.9B+4%+43%17%7.3×11.6%
Akeso 9926.HK$7.01B-48%+42%-25%12.9×n/a

How CStone Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CStone Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure2616.HKPeer medianRank in peer set
1-month return+15.9%-5.4%2nd highest of 21
6-month return-22.1%-17.3%10th lowest of 21
Distance from 52-week high-43.4%-39.3%9th lowest of 21
Revenue growth (TTM)+116.7%+5.9%2nd highest of 18
Operating margin-88.7%0.8%5th lowest of 18
EV / Sales17.0×7.6×3rd most expensive of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%17.0×n/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%10.4×44.1%-13.2%
Harrow HROWUnited States$1.21B+4%+21%1%4.7×n/an/a
Mabwell (Shanghai) Bioscience 2493.HKHong Kong$1.20B-29%+21%-127%13.6×n/an/a
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%818.8×n/an/a
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%10.4×n/an/a
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%1.8×7.0%-5.3%
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%7.6×n/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%8.6×n/an/a
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%13.3×n/an/a
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%13.2×n/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%0.5×n/an/a
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%2.6×-4.0%-9.0%
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%4.8×3.4%+27.9%
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%39.1×n/an/a
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%2.3×2.5%+15.5%
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%1.4×n/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%2.0×-0.4%-1.3%

Questions

Who are CStone Pharmaceuticals's main competitors?
Named competitors: Junshi Biosciences (1877.HK), Innovent Biologics (1801.HK), Akeso (9926.HK). The cockpit's measured peer set (industry) also includes Chongqing Lummy Pharmaceutical (300006.SZ), Harrow (HROW), Mabwell (Shanghai) Bioscience (2493.HK), D&D Pharmatech (347850.KS), Idorsia (IDIA.SW), Tianjin Chase Sun Pharmaceutical (300026.SZ).
Is CStone Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 17.0× against a peer median of 7.6×, 3rd most expensive of 18 in its peer set.
How has CStone Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -22.1% against -17.3% for the median peer; over one year +6.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.